Evidence map›Paper›PMID 32311895›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2020

[Safety and efficacy of patients with refractory B-lymphoblastic leukemia treated with anti-CD19 CAR-T cell bridging to allogeneic hematopoietic stem cell transplantation].

H Ai, Q S Yin, Q Wang, Y W Fu, X D Wei, Y P Song

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

H AiDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Q S YinDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Q WangDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Y W FuDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
X D WeiDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Y P SongDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Henan Cancer Hospital · CN

Funding

Henan Natural Science Foundation 22180003Program of Technologies of Henan Province 182102310381Project of Henan Medical and Technology Research (Co-construction of province and ministry) 201701028
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationAdolescentAdultAntigens, CD19ChildFemaleHumansMalePrecursor B-Cell Lymphoblastic Leukemia-LymphomaRetrospective StudiesT-LymphocytesTransplantation ConditioningYoung AdultAntigens, CD19Allogeneic hematopoietic stem cell transplantationB cell leukemiaCAR-T cellRefractory/relapsed

Identifiers

PMID32311895
PMCPMC7357920
OpenAlexW3025084914

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.